Company news
Veracyte, Inc. (NASDAQ:VCYT) news
Every Veracyte, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
Veracyte Announces First Quarter 2023 Financial Results
May 4, 2023
Veracyte Announces Release of Inaugural ESG Report
May 3, 2023
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
May 3, 2023
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
May 2, 2023
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
May 1, 2023
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
April 29, 2023
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
April 27, 2023
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
April 17, 2023
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
April 13, 2023
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
April 12, 2023
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
March 15, 2023
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
March 11, 2023
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
February 22, 2023
Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
February 15, 2023
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
February 13, 2023
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
February 6, 2023
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
February 1, 2023
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
February 1, 2023
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
December 15, 2022
Veracyte Announces Third Quarter 2022 Financial Results
November 2, 2022
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
November 1, 2022
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
October 27, 2022
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
October 25, 2022
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
October 24, 2022
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
October 18, 2022
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
October 13, 2022
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
September 22, 2022
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
September 13, 2022
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
September 11, 2022
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
September 7, 2022
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 1, 2022
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
August 31, 2022
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
August 11, 2022
Veracyte Announces Second Quarter 2022 Financial Results
August 2, 2022
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
July 20, 2022
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
July 14, 2022
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
July 13, 2022
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
June 27, 2022
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
June 20, 2022
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
June 3, 2022
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
May 31, 2022
Veracyte to Present at Upcoming Investor Conferences
May 26, 2022
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
May 26, 2022
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
May 26, 2022
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
May 16, 2022
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
May 12, 2022
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
May 12, 2022
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
May 4, 2022
Veracyte Announces First Quarter 2022 Financial Results
May 3, 2022
Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
May 2, 2022